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Abstract
Regulatory T cells (Tregs) suppress immune activation and are critical in preventing autoimmune diseases. While the ability
of Tregs to inhibit proliferation of other T cells is well established, it is not yet clear whether Tregs also modulate
inflammatory cytokines during an immune response. Here, we show that the expression of inflammatory cytokine receptors
IL-1R1 and TNFR2 were higher on resting mature Tregs compared to naı ¨ve or memory T cells. While upon activation through
the T cell receptor (TCR), expression of IL-1R1 and TNFR2 were upregulated on all T cell subsets, IL-1R1 maintained
significantly higher expression on activated Tregs as compared to other T cell subsets. The decoy receptor for IL-1 (IL-1R2)
was not expressed by any of the resting T cells but was rapidly upregulated and preferentially expressed upon TCR-
stimulation on Tregs. In addition, we found that Tregs also expressed high levels of mRNA for IL-1 antagonist, IL-1RA. TCR-
stimulation of naı ¨ve T cells in the presence of TGFb, which induces FOXP3 expression, however did not result in
upregulation of IL-1R1 or IL-1R2. In addition, ectopic expression of FOXP3 in non-Tregs, while causing significant
upregulation of IL-1R1 and IL-1R2, did not achieve the levels seen in bona fide Tregs. We also determined that resting
human Tregs expressing IL-1R1 did not have higher suppressive capacity compared to IL-1R1- Tregs, suggesting that IL-1R1
does not discriminate suppressive resting Tregs in healthy individuals. Functionally, activated human Tregs displayed a
capacity to neutralize IL-1b, which suggests a physiological significance for the expression of IL-1 decoy receptor on Tregs.
In conclusion, our findings that human Tregs preferentially express receptors for TNF and IL-1 suggest a potential function
in sensing and dampening local inflammation.
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Introduction
Regulatory T cells (Treg) are characterized by the ability to
suppress immune activation [1]. Tregs are a subset of CD4+ cells
and are typically identified based on CD25 and FOXP3
expression [1]. The latter is a transcription factor also necessary
for their development and function [1]. While it is well established
that Tregs are highly potent in inhibiting the activation and
proliferation of other T cell subsets in vitro and in vivo, the exact
mechanisms of this suppression are not fully understood [2].
However, evidence from mouse models suggests that Tregs may
have other anti-inflammatory properties in addition to suppressing
T cell activation [1,3]. For example, Tregs have been shown to
prevent T cell independant intestinal inflammation [4]. Little is
known on how Tregs mediate T cell-independent suppressive
mechanisms and whether the inflammatory milieu may have
modulatotry effects on the function of Tregs.
Recently, IL-1R1 and IL-1R2 were shown to be expressed on in
vitro expanded human Tregs [5] and TNFR2 was shown to be
expressed on murine and human Tregs [6]. IL-1R1 is a signaling
receptor for IL-1, which mediates its function [7]. IL-1R2, instead
neutralizes IL-1 either as a surface decoy receptor or in a cleaved
andsecreted form [7,8,9]. TNFR2isaninduciblereceptorforTNF,
that can trigger both cell survival and inflammatory signals [10].
In humans, Tregs comprise 2–5% of total CD4+ cells and similar
to mouse Tregs, are crucial for proper immune function, as their
absenceresultsinmassive autoimmunity[11].The canonicalmurine
Treg markers, FOXP3 and CD25, do not selectively define human
Tregs, since these markers can be induced on other human T cells
upon activation, especially in the presence of TGFb [12,13]. It was
recently shown that IL-1R1 and IL-1R2 can be useful markers to
purify Tregs from in vitro expanded cultures [5]. However, the
expressionpatternandfunctionofthesereceptorsonhumanTregsis
not yet fully characterized. Here, we show that IL-1R1 and TNFR2
are preferentially expressed on resting ex vivo isolated Tregs.
However, upon activation both of these receptors are upregulated
on other T cells subsets, although IL-1R1 maintains preferential
expression on Tregs. We also found that Tregs have the capacity to
neutralize IL-1b activity, suggesting that preferential expression of
IL-1b decoys by these cells has a functional consequence of possibly
suppressing the inflammatory cytokine milieu.
Results
Human Tregs preferentially express IL-1 and TNF
receptors and decoys of IL-1
In order to identify new effector molecules that may contribute
to Treg function, we had performed differential gene expression
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expression of CD25 and CD45RO: Naı ¨ve, (TN defined as CD25-
CD45RO2), Memory, (TM defined as CD252CD45RO+), Naı ¨ve
Treg, (TNreg defined as CD25+CD45RO2), and Treg
(CD25+CD45RO+) as described [14]. During the course of
analysis of this data set we found that several cytokine receptors,
IL-1R1, IL-1R2 and TNFR2, which were recently reported to be
preferentially expressed on human and murine Tregs [6,15] or in
vitro expanded human Tregs [5] were preferentially expressed on
resting or activated ex vivo human Tregs (data not shown). In
addition to these receptors we also found that the IL-1 Receptor
Antagonist (IL-1RA) was highly expressed preferentially on human
Tregs (data not shown), which has not been reported before.
Together, these expression profiles of pro-inflammatory cytokine
receptors and their decoys prompted us to further characterize
them phenotypically and functionally on human Treg subsets.
Next, we confirmed expression of IL-1R1, IL-1R2 and TNFR2
on Tregs and other T cell subsets. PBMC isolated from blood of
healthy donors were stained for CD3, CD4, CD25, and CD45RO
to separate them into four subsets (Fig. 1A), which were then
assessed for expression of IL-1R1 and TNFR2 using flow
cytometry (Fig. 1B and S1). IL-1R1 was either absent or expressed
at significantly lower levels on TN, TNreg and TM cells compared
to Tregs (Fig. 1B, 1C and Fig. S1). Tregs, and interestingly also
TNregs, expressed much higher levels of TNFR2 compared to TM
cells, and TN cells were mostly negative for TNFR2 expression
(Fig. 1B, 1C and Fig. S1). The addition of IL-2 to the cultures
enhanced expression of TNFR2 modestly across all subsets, and
IL-1R1 specifically on Tregs (Fig. 1B, 1C and Fig. S1).
In order to determine the expression of these receptors after T
cell activation, we stained purified CD4+ T cells that were
stimulated through the TCR. We have recently identified a cell
Figure 1. Expression of IL-1R1 and TNFR2 on human T cell subsets. (A) Total PBMC from healthy donors were stained with for CD3, CD4,
CD25, CD45RO, IL-1R1 and TNFR2 after resting overnight in culture with or without IL-2. Lymphocytes were gated on CD3+CD4+, which were further
gated into naı ¨ve (TN CD45RO2CD252), memory (TM, CD45RO+CD252), naı ¨ve Treg (TNreg, CD45RO2 CD25+), and Treg (CD45RO+CD25+). (B)
Expression of IL-1R1 and TNFR2 is shown for each subset. Data is representative of 6 different donors. (C) Results calculated as in (B) are shown for 6
donors with statistical analysis.
doi:10.1371/journal.pone.0008639.g001
IL-1 and TNF Receptors on Treg
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activated Tregs [14,16]. Because at 2 days post-activation, TN cells
still remain CD45RO negative, we used GARP and CD45RO as
markers to define activated Tregs following 2 day TCR
stimulation of total CD4+ cells (Fig. 2A). We then assessed
expression of IL-1R1, IL-R2 and TNFR2 on these activated
subsets. We found that IL-1R1 is preferentially expressed on Tregs
when compared to other activated subsets (Fig. 2B, 2C and Fig.
S2). TNFR2 expression increased on all subsets upon activation
(Fig. 2B and 2C) but was much higher on Tregs as determined by
analysis of the mean intensity of expression (Fig. S2). IL-1R2 was
also modestly induced on all T cells subsets upon activation, and
was highest on Tregs (Fig. 2B, 2C and Fig. S2).
We also observed high expression of IL-1RA mRNA in our
microarray analysis, which we then confirmed using quantitative
real time PCR in Tregs isolated from multiple donors (Fig. S3).
However, we were not able to detect any protein product using
intracellular cytokine staining, or multiplex cytokine assays with a
5 pg/ml limit of detection (data not shown). At this point we do
not know the reason for not being able to detect IL-1RA at the
protein level despite very high mRNA levels. It is plausible that this
protein is secreted at very low levels only, being neutralized
through IL-1R1 [17] or being rapidly degraded.
Time-course expression of IL-1R1, IL-1R2, and TNFR2 on
CD4+ subsets
To determine the expression of the IL-1 and TNF receptors on
sorted CD4+ subsets over-time after activation, we stimulated
purified TN,T M, TNreg, and Treg cell subsets using anti-CD3/
CD28 coated beads. These activated T cells were then cultured
and expanded in the presence of IL-2, and stained daily for
expression of IL-1R1, IL-1R2, and TNFR2. We found that IL-
1R1 peaked at day 2 post-activation on TM and TNreg cells
(Fig. 3A), and then gradually declined over time on these subsets
Figure 2. Expression of IL-1R1, TNFR2 and IL-1R2 on activated CD4+ T cell subsets. (A) Total CD4+ cells were activated with anti-CD3/CD28
coated beads for two days and stained for GARP, CD45RO, IL-1R1, IL-1R2, and TNFR2. Live cells were gated into TN (CD45RO2GARP2), TM
(CD45RO+GARP2), TNreg (CD45RO2GARP+), and Treg (CD45RO+GARP+). (B) Expression of IL-1R2, IL-1R1 and TNFR2 are shown for each population.
A representative donor is shown. (C) Statistical analysis of results shown in (B) from multiple donor blood.
doi:10.1371/journal.pone.0008639.g002
IL-1 and TNF Receptors on Treg
PLoS ONE | www.plosone.org 3 January 2010 | Volume 5 | Issue 1 | e8639Figure 3. Time-course of IL-1R1, IL-1R2 and TNFR2 expression on activated CD4+ T cell subsets. (A) Total resting CD4+ cells were sorted
based on CD25 and CD45RO expression into 4 subsets as described above. The subsets were then stimulated through the TCR and stained for IL-1R1,
TNFR2 and IL-1R2 daily. Histogram overlays of expression on resting (red), day 1 (blue) and day 2 (green) post activation are shown. (B–D) Percentages
of IL-1R1, IL-1R2 and TNFR2-expressing T cells over several days post- TCR-activation. (E) The amount of soluble IL-1R2 detected in the supernatant
from T cells washed and re-plated at 0.5610
6/ml daily, as determined by CBA.
doi:10.1371/journal.pone.0008639.g003
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expression of IL-1R1 compared to other subsets even 5 days after
activation (Fig. 3B). In contrast, TNFR2 was induced and
maintained on nearly all T cells 2–3 days post TCR-stimulation
(Fig. 3A, 3C), and therefore quickly lost its preferential expression
pattern on Tregs. The expression of IL-1R2 also peaked at day 2
post-activation on TM, TNreg and Treg subsets, but rapidly
declined to undetectable levels for both the cell surface and
secreted forms (Fig. 3D and 3E). Interestingly, TN cells did not
express any IL-1R2 during the time course of this activation
(Fig. 3D and 3E) and the expression of IL-1R1 on these cells was
also very modest even 5 days after TCR stimulation (Fig. 3B).
We next determined the expression pattern of the IL-1 and
TNF receptors on in vitro expanded T cells post reactivation. We
and others have shown that TNregs are precursors of canonical
Tregs in vitro and have much greater proliferative capacity when
compared to mature Tregs [18,19]. We therefore characterized
expression of IL-1R1, IL-1R2, and TNFR2 on TNreg, and TN
cells expanded for two weeks in culture in IL-2 containing media
and then reactivated through the TCR to generate mature Treg
and T effector (Teff) cells, respectively. We found that the
expression of IL-1R1, and IL-1R2 followed a similar pattern in in
vitro expanded Tregs (Fig. 4A, 4C and 4D) compared to those
isolated ex vivo (Fig. 3B, 3D and 3E). As such, IL-1R1 continued to
be expressed at higher levels on Tregs during in vitro expansion and
was further upregulated upon reactivation (Fig. 4A). IL-1R2, on
the other hand, is downregulated to background levels after two
weeks of expansion but was rapidly induced upon reactivation of
the Tregs (Fig. 4C and 4D). In contrast, the expression level of
TNFR2 was consistently high on both Tregs and Teff cells after
the in vitro expansion phase, albeit at slightly lower level on Teff
cells, which increased to Treg levels upon reactivation (Fig. 4B).
Regulation of IL-1R1 and IL-1R2 by FOXP3
The transcription factor FOXP3 is necessary, but not sufficient
for the development and function of Tregs [20]. Not all FOXP3-
expressing cells have suppressive capacity, as activation of T cells
in the presence of TGF-b induces FOXP3 without rendering them
suppressive [12,20]. To determine whether preferential expression
of IL-1 Receptors on Tregs is regulated by FOXP3 expression, we
either over-expressed FOXP3 in TN cells, or treated them with
TGFb to induce endogenous FOXP3. We found that ectopic
expression of FOXP3 did not induce IL-1R1 on in vitro expanded
Tregs (Fig. 5A). However, upon reactivation IL-1R1 was slightly
induced on FOXP3 overepxressing cells compared to control lines
(Fig. 5A), although this was still significantly less compared to bona
fide Tregs (Fig. 5B). TN cells activated in the presence of TGFb did
not upregulate IL-1R1, even after reactivation (Fig. 5B). A Similar
pattern of expression was also observed on these cells for the cell
surface and secreted forms of IL-1R2 (Fig. 5B).
In a reverse set of experiments, we assessed the expression of IL-
1 receptors on Tregs upon silencing FOXP3 expression. We found
that shRNA-mediated knockdown of FOXP3 modestly, but
reproducibly downregulated IL-1R1 and IL-1R2 expression in
Tregs (Fig. 5C). Collectively, these results indicate that FOXP3
makes a modest contribution to induction of IL-1R1 and IL-1R2
expression in Tregs. We did not perform similar experiments for
TNFR2 expression, since this receptor is already constitutively
expressed on all activated T cells.
Can expression of IL-1R1 be used to better define resting
bona fide Tregs?
Numerous reports have now shown that CD25 is an imperfect
marker for Tregs because it is also induced following activation of
Figure 4. Time-course of IL-1R1, IL-1R2 and TNFR2 expression on in vitro expanded and reactivated T cell subsets. Sorted TNregs and
TN cells were reactivated at least 14 days after initial stimulation to produce expanded Treg and Teff cells, respectively. (A–C) Cells were stained at day
14 post first activation and then daily after re-stimulation through TCR (day +1, etc). (D) Supernatants were harvested from the cells restimulated
washed and plated at 0.5610
6/ml daily and the level of soluble IL-1R2 was analyzed.
doi:10.1371/journal.pone.0008639.g004
IL-1 and TNF Receptors on Treg
PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8639Figure 5. Regulation of IL-1R1 and IL-1R2 expression by FOXP3. (A) Cells ectopically overexpressing FOXP3 were generated using lentiviral
transduction as described in the methods. Cells were restimulated, and stained two days later for GARP and IL-1R1 expression. (B) Expression of IL-R1,
IL-1R2 and secretion of soluble IL-1R2 in empty vector transduced, FOXP3 transduced, TGFb treated, and expanded Tregs. TGFb treated cells were
reactivated in the presence of TGFb1 (20 ng/ml) one week after initial activation. Expanded Tregs were gated on GARP+ cells to exclude non-Tregs in
the same cultures from the analysis. Data are average of three donors. (C) Comparison of IL-1R1 and soluble IL-1R2 expression on FOXP3 shRNA
lentivirus treated cells. After initial infection, expansion, and sorting, cells were reactivated and stained one day later. Supernatants were analyzed for
sIL-1R2 from cells plated at 0.5610
6/ml daily. Data are average of three donors.
doi:10.1371/journal.pone.0008639.g005
IL-1 and TNF Receptors on Treg
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contaminated with recently or chronically activated cells mas-
querading as Tregs [16]. We have recently shown that GARP,
which is specifically expressed on Tregs and TNregs upon
activation, is a useful marker for isolating highly pure activated
Tregs [16]. Similarly, IL-1R1 was recently used as a marker to
purify activated expanded human Tregs in vitro [5]. Since a portion
of resting Tregs express IL-1R1, we asked whether it could be
useful as a marker of ex vivo Tregs. To address this question, we
stained purified CD4+ T cells with CD25, CD45RO, and IL-1R1
antibodies and sorted Treg and TM cells into subsets based on IL-
1R1 expression (Fig. 6A). We then tested the suppressive capacity
of these cells at multiple ratios of suppressor to target T cells. We
found that there was no significant or reproducible difference in
suppressive capacity between IL-1R1+ versus IL-1R1- Treg cells
(Fig. 6B and Fig. S4). As expected, the IL-1R1+ or the IL-1R1-
memory subset did not show any significant suppressive activity
(Fig. 6B and Fig. S5). In conclusion, the expression of IL-1R1 does
not discriminate suppressive Tregs ex vivo, at least not those isolated
from healthy donors.
Can Tregs neutralize IL-1b through expression of decoys?
IL-1R2 is a well-characterized decoy form of the IL-1 receptor
that binds IL-1 without transducing intracellular signals
[21,22,23]. We therefore hypothesized that Tregs may directly
neutralize IL-1b through their surface expression and secretion of
IL-1R2. To perform this experiment we developed a highly
sensitive bioassay to determine functional neutralization of IL-1b,
which is outlined in Figure 7A. For this purpose we used human
fibroblasts, which secrete high levels of IL-6 and IL-8 in response
to low concentrations of IL-1b (Fig. 7). To determine whether T
cell expression of IL-1R2 can neutralize IL-1b in this bioassay, we
generated Jurkat T cells transduced to overexpress IL-1R2 (Fig.
S5). We then preincubated Jurkat cells with recombinant IL-1b
(10 pg/ml). After several hours of incubation, the IL-1b containing
T cell mixtures were transferred to pre-plated fibroblast cultures
(Fig. 7A). The secretion of IL-8 and IL-6 from the fibroblasts in
response to functional IL-1b was then measured after overnight
incubation (Fig. 7A). We found that Jurkat cells expressing IL-1R2
potently neutralized the effect of IL-1b compared to cells
expressing vector only (Fig. 7B).
We then asked whether the potent neutralization from Jurkats
overexpresing IL-1R2 is mostly due to its surface expression or the
secreted form. To address this we used CBA to measure the
amount of IL-1R2 secreted by IL-1R2 overexpressing Jurkats,
which was 4.5 ng/ml in this assay. We found that even twice the
amount of IL-1R2 found in Jurkat supernatants, when added to
fibroblasts in recombinant form, did not significantly neutralize
IL-1b function (Fig. 7B). Complete neutralization of IL-1b
required 50 fold higher concentrations (5 ug/ml) of recombinant
IL-1R2 (Fig. 7C). Thus, we concluded that much of the
neutralizing activity of Jurkat cells overexpressing IL-1R2 is
derived from the cell surface form, as has been previously
suggested for other cell types [24].
We then assessed the capacity of Tregs to neutralize IL-1b using
our bioassay. Addition of pre-activated expanded effector T cells
induced high secretion of IL-6 from fibroblasts (Fig. 7C). This high
background from Teff cells is expected, since they produce many
inflammatory cytokines that can stimulate fibroblasts to release IL-
6 or IL-8. Similarly, the addition of expanded Tregs to fibroblasts
also induced a background response, albeit at lower levels
compared to Teff cells (Fig. 7C). This was also not surprising
because we expected some level of background from Tregs due to
either contamination of non-Tregs in the culture [5] or secretion
of cytokines such as IL-17 from Tregs [25,26]. The background
from these cells could also be due to secretion of low levels of IL-
1b, however, we did not find any detectable levels of IL-1b
(,5 pg/ml) in either Teff or Treg cultures using CBA.
Nonetheless, addition of IL-1b to the cultures where Teff cells
were present caused fibroblasts to further increase IL-6 secretion
more than three-fold (Fig. 7C), suggesting that the background is
not due to the presence of endogenous IL-1b in these cultures. In
contrast to the Teff cells condition, addition of IL-1b to fibroblasts
in the presence of Tregs did not result in higher IL-6 secretion by
fibroblasts compared to Treg cells alone (Fig. 7C). Accordingly, we
calculated that, after accounting for the background, Tregs appear
to be as potent in IL-1b neutralizing capacity as recombinant IL-
1b decoys (Fig. 7D). Similar neutralization effects were measured
using IL-8 as a read-out in the supernatants (data not shown).
Discussion
Numerous in vivo and in vitro studies have demonstrated the
potent ability of Treg cells to suppress T cell activation and
proliferation, which could account for the critical role of Tregs in
preventing autoimmune diseases [1,27]. Our findings that Tregs
preferentially express the inflammatory cytokine receptors, IL-
1R1, TNFR2 and IL-1R2, suggest a novel role for these regulatory
cells in modulating inflammation.
IL-1b is a potent cytokine with pleiotropic functions [7], such as
stimulating angiogenesis at inflamed tissue sites, triggering
proinflammatory cytokine release from antigen presenting cells
(APCs) and contributing to the polarization of Th17 cells
[7,28,29]. Uncontrolled IL-1b, even at very low concentrations
can cause pathology [7]. IL-1R2, the decoy form of the receptor
has also been identified as deficient in human endometriosis,
which is thought to be an IL-1b-induced pathology [30,31,32].
Therefore, the ability of Tregs to express and release IL-1R2,
and possibly also IL-1RA, locally to neutralize IL-1b function
could play an important role in dampening inflammation and
autoimmunity.
The functional significance of expression of IL-1R1 and
TNFR2 on Tregs is less clear. IL-1b is known to enhance the
proliferation of conventional T cells [33], and studies in mice have
also shown that IL-1 enhances expansion of FOXP3+ cells [34],
thus preferential expression of IL-1R1 by Tregs could confer them
with heightened sensitivity to IL-1 over other CD4+ subsets to give
them a proliferative advantage. Alternatively, Tregs may express
high levels of IL-1R1 simply to compete for IL-1b in the
microenvironment, while remaining hyporesponsive to its effects,
akin to the constitutive expression of the IL-2 receptor CD25 by
Tregs, which has been proposed to deprive nearby T cells of IL-2
signals [35]. Conversely, IL-1 signals may negatively regulate or
switch the phenotype of Tregs. In support of this, it was recently
shown that IRAK2/2 mice have higher Treg proportions
compared to wild type mice, suggesting that IL-1 signaling could
be negatively regulating Treg development or maintenance [36].
Similarly, IL-1b, in combination with IL-2 was recently shown to
convert natural human Tregs into Th17 lineage cells [28].
Although deficiency or defects of Treg cells cause severe
inflammation and autoimmunity in vivo, recent studies have even
shown that Tregs may have pro-inflammatory properties in certain
scenarios, for example, by producing IL-17 [25] or by coordinat-
ing protective response against HSV-2 infection [37].
We found that TNFR2 is also preferentially expressed on resting
Tregs and is upregulated on Tregs with faster kinetics upon TCR
stimulation compared to other T cell subsets. However, it is not yet
clear why TNFR2 is preferentially maintained on Tregs. Since
IL-1 and TNF Receptors on Treg
PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8639Figure 6. Suppressive capacity of IL-1R1 expressing Tregs. (A) Total resting CD4 cells were stained for CD25, CD45RO, and IL-1R1 expression.
Cells were gated on Treg and TM as described in figure 1 and further sorted based on expression of IL-1R1. Since TN cells lack IL-1R1 expression, these
cells were used to set the sort gate. (B) Suppression of TN target cells by Tregs or Teff cells was measured for various concentrations of OKT3 and
various suppressor: target ratios using the Treg suppression assay described in the methods. One representative OKT3 concentration is shown.
doi:10.1371/journal.pone.0008639.g006
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cell survival [10], this may be a mechanism for Treg maintenance
at the site of inflammation through TNF signaling. TNFR2 can
also function to enhance signaling through TNFR1 by increasing
the concentration of TNF on the cell surface [10,38] and is
involved in costimulation of T cell activation [39].
Figure 7. Can Tregs neutralize IL-1b activity? (A) Schematic of neutralization assay, as described in the methods. (B) Jurkat cells (10,000 cells)
were cultured with recombinant IL-1b (10 pg/ml), incubated for 4 hours, and then transferred to pre-plated fibroblasts (1000 cells). Twice the amount
of recombinant rhIL-1R2 (9 ng/ml) secreted by Jurkat cells overexpressing IL-1R2 was similarly preincubated with IL-1yA ˆand added to fibroblasts.
After overnight incubation, supernatants from the fibroblasts were collected and tested for IL-6 and IL-8 using CBA. Data are average of duplicate
wells and are representative of three experiments. (C) Using the same set up as described in (A), expanded Treg or Teff cells were tested for
neutralization. Recombinant rhIL-1R2 (5 ug/ml) was used as a positive control for neutralization of all IL-1b. Data are representative of 3 donors. (D)
Percent neutralization, calculated as described in methods, was averaged for 3 donors.
doi:10.1371/journal.pone.0008639.g007
IL-1 and TNF Receptors on Treg
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function and in vitro expansion of Tregs [6]. It was also shown that
murine Tregs have the ability to neutralize TNF through shedding
of TNFR [40]. In in vitro experiments it was also shown that
soluble exogenous TNF abrogated suppression of T cell prolifer-
ation by Tregs [15]. Conversely, a recent study in malaria patients
showed a correlation between serum levels of TNF, TNFR2
expression by Tregs, and enhanced Treg suppressive activity [41].
Analysis of healthy donors in the same study showed that
TNFR2+ Tregs were more suppressive than their TNFR2-
counterparts, suggesting that TNF signaling enhances suppressive
function in human Tregs [41]. Careful delineation of the TNF
response in human Tregs will be required to reveal subtle roles of
TNF during autoimmune conditions and help to resolve
contrasting reported findings.
Our FOXP3 silencing experiments partly implicate this
transcription factor in induction of IL-1R1 and IL-1R2 expression
on Tregs. Interestingly, we did not observe any significant
expression of IL-1Rs on T cells stimulated with TGFb to induce
FOXP3. Even ectopic over-expression of FOXP3 at levels greater
than in bona fide Tregs resulted only in modest expression of these
receptors. A similar expression pattern is seen for GARP
expression by T cells, in which ectopic over-expression of very
high levels of FOXP3 could induce only very low levels of GARP
[16]. Indeed, numerous reports have now confirmed that FOXP3
is not sufficient for bona fide human Treg cell differentiation, and
that other transcription factor(s) could be required for full Treg cell
programming [20,42]. Alternatively, Tregs may have undergone
chromatin changes during differentiation that better allow FOXP3
either directly or indirectly to turn on target genes [43]. Full
expression of GARP and IL-1Rs in T cells may therefore require
additional transcription factors or the bona fide Treg chromatin
pattern.
Currently, identification of resting human Treg cells relies on
expression of high levels of CD25 and expression of FOXP3.
While these markers identify Tregs reliably in healthy individuals,
chronic immune activation in diseases such as HIV infection can
confound identification of Tregs due to an increase in effector T
cells with a similar phenotype [16]. We have recently identified the
cell surface molecule GARP as a highly specific marker for
isolating recently activated Tregs, however GARP is not expressed
on any resting Tregs [16], and thus is only useful in defining Tregs
after activation. Recently, Tran et al. showed that IL-1R1, among
other markers, could be utilized to purify expanded Treg
populations in vitro, which are normally contaminated with
overgrowth from non-Treg cells present in initial CD25+ sorts
[5]. Our results that expanded Tregs express higher levels of IL-
1R1 compared to expanded effector T cells complement these
findings. However, our experiments with resting ex vivo derived
Tregs suggest that IL-1R1+CD25+ T cells are not significantly
enriched with suppressive Tregs compared to IL-1R1-CD25+ T
cells. We conclude that IL-1R1 expression does not affect Treg
ability to suppress T cell proliferation when isolated from healthy
individuals, but more likely represents a specialized subset of Tregs
that are more equipped to respond to IL-1 at the site of
inflammation. It is possible, however, that IL-1R1 could be a
Treg-specific marker in chronic activation disease conditions such
as HIV infection, in which higher levels of CD25+ cells that are
not suppressive are present, possibly due to chronic immune
activation [16,44].
In summary, our findings reveal that Tregs, besides controlling
T cell activation, may have an additional function of suppressing
pro-inflammatory cytokines. In addition, the expression of TNF
and IL-1 receptors on Tregs may have important functions in
modulating their differentiation or homeostasis during chronic
immune activation or inflammation.
Materials and Methods
Cell purification and culture
Blood samples were obtained from anonymous healthy donors
as buffycoats (New York Blood Center). New York Blood Center
obtains written informed consent from all participants involved
in the study. Because all the samples were sent as anonymous,
Institutional Review Board at New York University medical
center determined that our study was exempt from further ethics
approval requirement. Peripheral Blood Mononuclear cells
(PBMC) were isolated with Ficoll-Hypaque (Amersham Phar-
macia). CD4+ T cells were isolated from PBMC using magnetic
bead sorting (Invitrogen, Dynabeads) and monocyte derived
dendritic cells (DC) were generated from CD14+ cells as
previously described [45]. Purified cells were cultured in RPMI
(Life Technologies, Carlsbad, CA) media containing fetal calf
serum (FCS) (Atlanta Biologicals, Lawrenceville, GA) as
previously described [45]. To activate cells for expansion in
vitro and in experiments other than suppression assays, anti-
CD3 and anti-CD28 coated beads (Dynabeads, invitrogen) were
used at a bead: cell ratio of 1:4 in media containing IL-2
[45].
Real-time PCR analysis
Total RNA was isolated from flash-frozen cells using Qiagen
RNeasy mini kit, and cDNA generated using High capacity
reverse transcriptase kit (Applied Biosystems). Taqman primer/
probe mixtures were purchased from Applied Biosystems: IL-1RA
(Hs00277299_m1) b-Actin (Hs99999903_ml). Samples were run
on applied Biosystems 7300 apparatus. Data were normalized to
b-Actin for each sample.
Staining with antibodies and FACS analysis
Cells were stained in complete RPMI media or PBS+2% FCS
and 0.1% sodium azide for 30 minutes at 4uC and washed before
running on BD LSR-II flow cytometer. Cell sorting was done
using BD FACS Aria (BD Biosciences). Data was analyzed using
FlowJo software (Treestar) and gated on live cells based on forward
and side scatter properties. In samples of recently activated cells,
non-specific background from the beads was gated out in an
irrelevant channel. The following antibodies were used in the
stainings and sortings: CD25-PE, CD25-APC, CD45RO-FITC
(BD Pharmingen) and CD-45RO-Pacific Blue (Biolegend), IL-
1R1-PE (R&D systems FAB226F), TNFR2-Fluorescein (R&D
systems FAB226F), FoxP3-APC (Biolegend), IL-1R2-biotin (BD
pharmingen 552402), GARP pure (Alexis Biochemicals), and
secondary antibodies; streptavidin-APC (eBioscience), anti-
mIgG2b biotin (BD Pharmingen), and streptavidin APC (BD
Pharmingen). For samples co-stained with GARP and IL-1R2, a
directly conjugated secondary anti-mouse IgG (BD Pharmingen)
was used after GARP instead of the biotinylated secondary
antibody.
Cytokine measurements in supernatants
Cytokine Bead Assay (CBA) flex sets were purchased from BD
bioscience for human IL-1R2, IL-1b, IL-6, and IL-8. Experiments
were preformed according to the manufacturer’s instructions and
samples were run on BD LSR-II flow cytometer. Geometric mean
intensities for each bead were normalized to a standard
recombinant protein curve for each cytokine.
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Resting Naı ¨ve CD4+ cells (targets) were labeled with CFSE and
plated at 3610
4/well in 96-well u-bottom plates. Suppressor cells
were added at various ratios, and cells were activated using DC
(generated as described above) at a DC: target cell ratio of 1:10
and anti-CD3 antibody (ATCC clone OKT-3) at 10–100 ng/ml.
All cells were washed at least twice in complete media to remove
any cytokines. CFSE dilution was measured on BD LSRII flow
cytometer 4 and 5 days later. Percent suppression was calculated
as previously described [18].
Ectopic gene expression and shRNA mediated gene
silencing
IL-1R2 cDNA was purchased from Origene technologies and
subcloned into a lentiviral vector. FOXP3 was cloned as previously
described [45], and FOXP3 antisense oligos were generated as
previously described [14]. Lentiviruses expressing IL-1R2, FOXP3
or a FOXP3 shRNA oligo were generated as previously described
[45]. Freshly sorted TN or TNreg CD4+ cells were activated with
anti-CD3/CD28 beads at a bead: cell ratio of 1:4, and transduced
with a multiplicity of infection of 3. Cells were expanded in IL-2
containing media for 2 weeks and sorted for their GFP or RFP
marker genes using BD FACS Aria before reactivation. Sorted
cells were used to measure soluble protein levels whereas unsorted
cells were used for stainings.
Neutralization assay
Human bone marrow fibroblasts (obtained from NDRI)
expanded for 18 days, were plated in 6 well plates at 15610
4/
well and rested in RPMI for at least one day. Cells were
trypsinized and re-plated in 96-well flat bottom plates at 10
3 cells/
well for at least 4 hours and media was aspirated before addition
of T cells and IL-1b. Supernatants were taken and frozen 8–
12 hours later and analyzed as described above. Percent
neutralization was calculated as [amount of IL-6 induced from
recombinant IL-1b alone]–[amount of IL-6 induced in the
presence of T cell from recombinant IL-b alone] divided by
[amount of IL-6 induced from recombinant IL-1b alone].
Recombinant IL-1b and sIL-1R2 were purchased from R&D
systems. Recombinant IL-6 and IL-8 used to generate standard
curves were provided with the BD CBA flex set kit.
Statistical analysis
Receptor expression statistics in total PBMC, CD4+ cells, and
FOXP3 overexpressing cells were done using a paired, two tailed
t-test. Analysis of FOXP3 knockdown cells was done using a
paired one-tailed t test. Suppression Assay statistics were done
using a two-tailed paired t test. All statistics were done using
GraphPad Prism software.
Supporting Information
Figure S1 Expression of IL-1R1 and TNFR2 on resting CD4+
subsets. Histogram overlays of isotype controls (red) and specific
antibody (blue) with the percent of positive cells, shown for IL-1R1
and TNFR2 expression in CD4+ subsets analyzed from freshly
isolated total PBMC. Geometric means of fluorescence intensity
are shown in parentheses.
Found at: doi:10.1371/journal.pone.0008639.s001 (0.60 MB TIF)
Figure S2 Expression of IL-1R1, TNFR2 and IL-1R2 on
activated CD4+ subsets. Histogram overlays of isotype controls
(for IL-1R1 and TNFR2 stainings) or secondary only (for IL-1R2)
staining. Geometric means of intensity are shown in parentheses.
Found at: doi:10.1371/journal.pone.0008639.s002 (0.64 MB TIF)
Figure S3 Expression of IL-1RA mRNA in CD4+ subsets.
mRNA levels of IL-1RA are shown for different CD4+ subsets. T
cells were sorted as described above and activated with anti-CD3/
anti-CD28 coated beads overnight. cDNA was prepared as
described in methods, and real time PCR analysis for IL-1RA
was done. Data are normalized to b-Actin levels and are shown as
fold expression over the lowest expressing subset.
Found at: doi:10.1371/journal.pone.0008639.s003 (0.35 MB TIF)
Figure S4 Suppression of T cell activation by IL-1R1+ or IL-
1R1- Tregs. Graphical representation of percent suppression of
data in figure 6B. Statistical analysis was performed using different
suppressor: target ratios.
Found at: doi:10.1371/journal.pone.0008639.s004 (0.59 MB TIF)
Figure S5 Ectopic expression of IL-1R2 on Jurkat cells. FACS
histogram overlay of IL-1R2 expression in Jurkat cells were
transduced with IL-1R2 encoding lentivirus (blue) or empty vector
control (red). Both viruses encode GFP as amarker, thus cells were
stained for IL-1R2 and gated on GFP+ cells.
Found at: doi:10.1371/journal.pone.0008639.s005 (0.31 MB TIF)
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